Home » Stocks » TRIL

Trillium Therapeutics Inc. (TRIL)

Stock Price: $18.71 USD -1.42 (-7.05%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $18.75 +0.04 (0.21%) Dec 1, 7:58 PM

Stock Price Chart

Key Info

Market Cap 1.84B
Revenue (ttm) 94,656
Net Income (ttm) -31.77M
Shares Out 98.38M
EPS (ttm) -2.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $18.71
Previous Close $20.13
Change ($) -1.42
Change (%) -7.05%
Day's Open 20.54
Day's Range 18.66 - 20.71
Day's Volume 1,548,862
52-Week Range 0.30 - 20.71

More Stats

Market Cap 1.84B
Enterprise Value 1.82B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 98.38M
Float n/a
EPS (basic) n/a
EPS (diluted) -2.90
FCF / Share -1.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.94M
Short Ratio 4.78
Short % of Float n/a
Beta 1.88
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19,445.65
PB Ratio 10.63
Revenue 94,656
Operating Income -27.05M
Net Income -31.77M
Free Cash Flow -19.26M
Net Cash 17.30M
Net Cash / Share 0.18
Gross Margin 100.00%
Operating Margin -28,579.03%
Profit Margin -33,566.10%
FCF Margin -20,348.39%
ROA -19.01%
ROE -189.45%
ROIC -943.00%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(10.69% upside)
Current: $18.71
Target: 20.71
*Average 12-month USD price target from 7 stock analysts.

Financial Performance

Financial numbers in millions CAD.

Financial Overview

Gross Profit0.12------
Operating Income-35.44-36.37-41.00-33.72-21.23-13.17-4.30
Net Income-41.62-32.87-45.09-31.73-14.73-12.88-4.29
Shares Outstanding14.6913.157.857.804.430.15-
Earnings Per Share-1.65-2.35-4.61-4.06-2.22-3.06-3.16
Operating Cash Flow-24.91-30.46-27.04-22.85-18.30-7.45-2.48
Capital Expenditures-0.32-0.06-0.47-2.97-0.75-0.17-0.03
Free Cash Flow-25.23-30.52-27.51-25.82-19.05-7.62-2.52
Cash & Equivalents22.6733.3964.9150.4786.7726.1732.98
Total Debt---
Net Cash / Debt22.6733.3964.9150.2886.5025.8832.64
Book Value-0.1730.5962.3658.1285.8024.3033.91
Numbers in millions CAD, except per-share numbers.

Company Profile

Company Details

Full Name Trillium Therapeutics Inc.
Country Canada
CEO Jan Skvarka

Stock Information

Ticker Symbol TRIL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TRIL


Trillium Therapeutics, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.